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Interventional management of gastroduodenal
lesions complicating intra-arterial hepatic
chemotherapy
Abstract Herein we report the effi-
cacy of embolization of small patent
gastric or duodenal vessels for treating
gastroduodenal complications after
hepatic arterial infusion therapy
(HAIC). Catheter ports were im-
planted percutaneously from a femoral
approach in three cases or surgically
in the gastroduodenal artery in two
cases. Acute abdominal pain devel-
oped on average after four HAIC
courses of 5FU-oxaliplatin, mytomy-
cin, oxaliplatin or fotemustine. Esopha-
gogastroduodenoscopy showed
gastroduodenal lesions (gastroduodeni-
tis with or without ulcerations) in all
cases. Despite the interruption of the
HAIC, symptoms persisted and led to
selective hepatic arteriography showing
a patent right gastric artery (n=4) or a
recanalized gastroduodenal artery (n=1)
responsible for gastroduodenal misper-
fusion. Successful embolizations of the
arteries responsible for gastroduodenal
misperfusion (right gastric artery in four
cases and gastroduodenal artery in one
case) using 0.018 platinium coils re-
lieved the patients’ symptoms and
allowed the HAIC to continue. In gas-
troduodenal complications of HAIC, a
selective hepatic arteriography should
be performed to search any artery
responsible for the misperfusion of
the toxic agent in the gastroduodenal
area. Embolization of these arteries
allowed the HAIC to be restored.
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Introduction
As compared to intravenous systemic chemotherapy, intra-
arterial hepatic chemotherapy has several theoretical
advantages [1–3]. Because liver metastases receive most
of their blood supply from the hepatic artery, they will be
treated with higher drug concentrations with hepatic
arterial infusion therapy (HAIC) than with systemic
chemotherapy [1–3]. As compared to intravenous chemo-
therapy, concentrations of drugs in the tumor have been
determined to be 5–20 times greater depending on the drug
used [1]. Chemotherapeutic agents administered arterially
will be extracted mainly by the liver, thus reducing
systemic toxicity [2, 3].
Intra-arterial hepatic catheters can be placed surgically
or percutaneously [4]. The most common site of surgically
implanted catheter systems is the gastroduodenal artery
(GDA) [5], whereas in the percutaneous approach a
catheter is placed in the most suitable hepatic artery and
may be associated with the embolization of the GDA and
other aberrant hepatic arteries [4].
Gastroduodenal arterial blood supply not only arises
from the celiac trunk and the splenic artery through the left
gastric artery and the left gastro-epiploic artery, but also
from small branches arising from the hepatic artery through
the right gastric artery and duodenal arteries (Fig. 1). When
these small branches are not ligated or embolized when the
catheter is implanted, they may lead to inadvertent chemo-
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therapy perfusion of the gastroduodenal wall [6, 7].
Gastroduodenal complications are refractory to medical
treatments including antiacids and usually require inter-
ruption of HAIC [8].
We report five cases of documented gastroduodenal
HAIC complications successfully treated by embolization
of the arterial vessels responsible of gastroduodenal
misperfusion. We describe the outcome of these patients
and the possibility of continuing HAIC after embolization.
Materials and methods
Patients Out of 35 patients treated with HAIC for
unresectable metastatic hepatic lesions in two institutions
over a 15-month period, 5 patients (4 women and 1 man),
aged 32–69 years (mean age of 56 years), developed
gastroduodenal symptoms. All patients had biopsy-proven
metastases originating from colorectal cancer (n=3),
epidermoid carcinoma of the anal canal (n=1) and choroid
melanoma (n=1). None of our patients had previous
history of gastroduodenal ulcers.
In three patients, the indwelling catheter-port system
was implanted percutaneously via the femoral artery in
the proper hepatic artery (B: Braun ST 305C, Emmen-
brücke, Switzerland). We used the technique described
by Herrmann et al. [4]. The common femoral artery is
punctured using the Seldinger technique and the catheter
advanced to the celiac trunk to assess the anatomy and
possible variant hepatic arterial supply. No anatomical
variation was encountered in our three patients. The
catheter tip was placed into the GDA with the distal hole
placed at the origin of the hepatic artery to allow for
HAIC. The GDA was subsequently embolized by several
coils. No complications occurred during the procedures.
The two other patients underwent open surgical
implantation of the catheter [5]. Preoperative percutaneous
hepatic arteriography allowed us to exclude any hepatic
anatomical variation. The GDA was dissected and ligated
2–3 cm distally from its origin. In the proximal portion of
the GDA, the catheter was fixed in order to have its
extremity in the hepatic artery. The surgeons ligated the
gastric and duodenal branches originating from the hepatic
artery.
Both groups of patients underwent a nuclear-medicine
liver perfusion scan before the infusion of chemo-
therapeutic agent in order to exclude any extrahepatic
misperfusion.
HAIC courses consisted of 5FU-oxaliplatin (5FU:
1,000 mg/m2 and oxaliplatin: 85 mg/m2 once every
3 weeks), mytomycin (8 g/m2 every 4.5 weeks), oxalipla-
tin (100 mg/m2 every 3 weeks) (for two patients) or
fotemustine (200 mg/m2 every week for 4 weeks followed
by 200 mg/m2 every 3 weeks).
Upper gastrointestinal symptoms consisted of persistent
severe abdominal pain located in the right upper quadrant.
Nausea or hematemesis was not encountered. Pain devel-
oped on average after four HAIC courses (range: two to
six courses) and necessitated the interruption of the HAIC.
All patients underwent esophagogastroduodenoscopy
showing gastroduodenal lesions. The lesions consisted of
nonspecific inflammatory changes associated with (n=4)
or without (n=1) ulcerative lesions. Bleeding was noted
oozing from several points of the ulcer in one patient. The
ulcerations were located in the gastric pyloric sphincter in
four patients and also affected the duodenal bulb in one
patient.
Upper abdominal pain was refractory to conservative
treatment with omeprazole (20 mg twice a day) for an
average of 40 days. No antalgic treatment was reported.
An arteriography realized from the catheter-port system
allowed the right position of the catheter to be checked in
its original location and showed a patent RGA (n=4) or a
recanalized GDA (n=1, percutaneously implanted catheter
associated with the gastroduodenal artery embolization) to
be responsible for gastroduodenal misperfusion.
Procedures A 5-French catheter (Simmons 2 or Cobra 2,
Glidecath, Terumo, Tokyo, Japan) was inserted from the
right femoral artery in the celiac trunk to perform an
angiography of hepatic arteries and branches. In four
Fig. 1 Gastric arteries. 1 Aorta, 2 celiac trunk, 3 right inferior
phrenic artery, 4 left inferior phrenic artery, 5 splenic artery, 6 left
gastric artery, 7 left gastroepiploic artery, 8 trunk of the hepatic
artery, 9 gastroduodenal artery, 10 right gastric artery, 11 right
gastroepiploic artery, 12 hepatic artery
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patients a patent RGA originating from the hepatic artery
and in one patient a recanalized GDA (percutaneously
implanted catheter associated with the GDA embolization)
were demonstrated.
A 2.7-French microcatheter (Progreat, Terumo, Europe
N.V. Belgium) was inserted coaxially in the RGA (n=4)
or in the GDA (n=1). Positioning in the RGA was
performed anterogradely, via the left hepatic branch
(n=3) (Fig. 2) or retrogradely via the left gastric artery
(n=1) (Fig. 3). Embolization was done using 3–2 mm,
2-3 mm, or 5–2 mm Tornado soft platinum microcoils
(0.018 in) (Tornado, COOK Europe).
Results
Successful embolizations of the arteries responsible for
gastroduodenal misperfusion (RGA in four cases and GDA
in one case) relieved the patients and allowed the regional
chemotherapy to be continued. Pain was relieved an
average of 15 days (2–29 days) after embolization. The
decision to resume HAIC was based on pain relief.
HAIC could be restarted for an average of 6.2 courses
(2–10 courses).
None of the patients complained of further upper
gastrointestinal symptoms.
Coil migration in the left hepatic artery occurred in one
case, however the patient did not suffer left hepatic artery
occlusion, and collaterals from the right hepatic artery were
shown to have perfused the left lobe on the Technetium
microspheres nuclear-medicine study.
One patient had to stop his intrahepatic chemotherapy
because of a necrotizing cholangitis complicating HAIC
after 12 courses, and the 4 other patients because of
extrahepatic tumoral dissemination despite an hepatic
tumoral lesion stabilisation.
Discussion
HAIC is a very efficient technique for the treatment of
unresectable hepatic metastasis [1–3], but its use has been
limited because of associated complications such as biliary
3Fig. 2a–c A 55-year-old man treated with HAIC for liver
metastasis from colon cancer, presenting with epigastric pain.
Intra-arterial port-catheter system was surgically implanted. a Celiac
arteriogram with a Simmons 5-French catheter showing hepatic
artery and its branches. Note that the right gastric artery (arrows)
arises from the left hepatic branch. b Right gastric arteriogram
(arrow) via microcatheter coaxially advanced from the 5-French
catheter placed in the common hepatic artery. c Common hepatic
arteriogram obtained after embolization of the right gastric artery by
3–2 mm Tornado soft platinum microcoils
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ischemic and/or toxic cholangiopathy, arterial occlusion or
dissection, misperfusion of the agent and catheter dys-
function [8, 9]. One of the most common complications,
not encountered in patients treated with systemic chemo-
therapy [2, 3], is gastroduodenal ulcer, which occurs
mainly after the first and second course of HAIC and which
is considered to be a contraindication to continue [8].
Gastroduodenal complications were reported in 22% of
patients in the series of Barnett et al. [9] reporting com-
plications of HAIC in 4,580 patients.
GI lesions should be recognized as soon as possible
because of the potentially fatal complications of perforation
or upper gastrointestinal bleeding [10–12].
Esophagogastroduodenoscopy is strongly indicated to
confirm the diagnosis in patients under HAIC who develop
epigastric pain [12]. Gastroduodenal endoscopy allows the
distribution of the ulcers in the territories of the mis-
perfused arteries to be confirmed. The use of methylene
blue administration via the arterial port during endoscopy
has been used to establish gastroduodenal misperfusion
from HAIC [13, 14]. Gastroduodenal abnormalities ranged
from typical benign ulcers to a pattern of epithelial atypia
and multiple ulcerations that may be falsely considered
malignant [6]. Although the mucosal changes can be
morphologically alarming, histological features indicative
of HAIC-associated atypia have been established to dif-
ferentiate it from carcinoma [7]. Chuang et al. [15] reported
that 10 of the 18 patients (out of 174) presenting upper
gastrointestinal pain had acute gastroduodenal lesions
confirmed by endoscopy (n=7) or upper gastroduodenal
examination (n=3): 6 gastritis with gastric ulcers, 2
duodenal ulcers, 1 pyloroduodenitis and one pancreatitis.
Endoscopically the iatrogenic ulceration and gastritis were
located in the distribution of the infused arteries [15].
The pathogenesis of gastroduodenal complications after
HAIC is probably multifactorial. The distribution of lesions
follows vascular territories suggesting either an ischemic
and/or a direct toxicity. These complications seem to be
more frequent with 5-FU although they can be observed
with other drugs [9] suggesting a predominantly toxic
origin. Mucosal gastroduodenal ischemia has been related
to the ligature or embolization of arterial supply and to the
direct traumatic effect of the catheter and sutures in the
intestinal wall [10, 16]. Stress associated with the treatment
may also play a role [10].
Treatment of these GI lesions is usually associated
with antiulcer drugs as well as pain-control treatment,
and HAIC is usually stopped because of the fear of
recurrence [8, 10, 12]. In our series, embolization relieved
pain and symptoms very quickly and allowed the HAIC
treatment to be restored. This observation suggests that the
toxic effect of drugs on the gastroduodenal wall is the most
likely cause of these complications. Furthermore, emboli-
zation, which probably increases ischemia in this area, was
surprisingly efficient for relieving symptoms.
Fig 3a–d A 32-year-old
woman treated with HAIC for
liver metastasis from choroid
melanoma. Upper abdominal
pain motivated an esophago-
gastroduodenoscopy that
showed a 2.5-cm gastric ulcer
on the lesser curbure of the
stomach. Intra-arterial port-
catheter system was surgically
implanted. a Celiac arteriogram
with a Cobra 5-French catheter
showing the hepatic artery and
its branches. Note that the right
gastric artery (arrow) can be
seen. b Arteriogram obtained
via 5-French catheter placed in
left gastric artery shows com-
munication between left and
right gastric arteries. c Micro-
catheter advanced into right
gastric artery from left gastric
artery. d Common hepatic arte-
riogram obtained after emboli-
zation of right gastric artery by
2–3 mm Tornado soft platinum
microcoils (arrow)
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The surgical team of Hohn et al. [17] recommended
ligature of all the small arteries originating from the hepatic
artery and feeding the gastroduodenal region, GDA, RGA
and also narrow arteries. None of their patients presented a
gastrointestinal complication.
Song et al. [18] reported the importance of identification
of nonhepatic arteries arising from the proper hepatic artery
or from its distal branches before hepatic chemoemboliza-
tion in order to adopt adequate preventive measures to
avoid complications caused by nontarget perfusion. Em-
bolization of the arteries responsible for misperfusion
seems to be the most adequate approach. Although RGA
embolization seems to present technical problems because
of the RGA’s relatively narrow lumen and its sharp branch
[15, 19], Inaba et al. [19] described two techniques allow-
ing successful embolization in 201 out of 217 patients. The
embolization was performed either anterogradely via the
hepatic artery (189 patients) or via the left gastric artery
(12 patients).
Sofocleous et al. [20] reported 27 successful emboliza-
tions in 24 patients showing misperfusion on nuclear-
medicine liver perfusion scan done within 2 weeks of
surgical placement of the catheter tip in order to prevent
any complication. We certainly agree with this approach. In
our cases, when the catheter was placed, arteries allowing
misperfusion were not recognized probably because of
their small diameter. They may have increased in size
afterwards because of the occlusion of the gastroduodenal
artery related to catheter fixation.
Bloom et al. [14] reported 16 patients with liver
metastasis from colorectal carcinoma and HAIC misperfu-
sion. They separated the patients in two groups, extra-
hepatic (n=8) and intrahepatic (n=8) misperfusion. Five
patients out of the extrahepatic group presented gastro-
intestinal symptoms associated with gastroduodenal mis-
perfusion. This was confirmed by an endoscopy, performed
simultaneously with methylene blue injection in the arterial
port, whereupon the mucosa was observed to be stained
blue. However no mucosal lesions were described. Three
of these patients were sucessfully treated by percutaneous
embolization of the vessels responsible for gastroduo-
denal misperfusion. The authors suggested that intra-
hepatic and extrahepatic misperfusion were caused mostly
by inadequate angiographic evaluation of anatomical
variants, failure to ligate vessels and to redistribute extra-
hepatic blood flow to collateral channels after catheter tip
placement.
We must keep in mind that even with the pretreatment
occlusion of the aberrant hepatic arteries, patients with
hepatic tumors adjacent to the hepatic surface have the
potential to develop collaterals to the liver during HAIC
[21]. In the same way, newly developed abnormal branches
may be responsible for gastroduodenal misperfusion,
though gastroduodenal misperfusion may result from
repermealisation of GDA and/or RGA or from newly
developed collaterals to the stomach or the duodenum. Seki
et al. [22] reported two cases of gastric toxicity related to
HAIC, caused by the inflow of infused drugs via the left
inferior phrenic artery arising from the celiac trunk, which
was identified by digital subtraction angiography using the
indwelling catheter. It is important to determine where the
gastroduodenal misperfusion arises.
Gastroduodenal complications following HAIC should
prompt arteriography of the hepatic arterial circulation. An
evaluation to determine the presence of arteries that supply
the gastroduodenal region that may be perfused during
HAIC should be performed. If present, these vessels should
be embolized as this may result in resolution of symptoms
and continuation of HAIC.
To our knowledge this is the first clinical study
describing the endovascular management of gastroduode-
nal documented lesions complicating HAIC, suggesting
direct toxicity of the drug more than ischemic lesions.
Furthermore in our study, this management allowed
restoration of treatment increasing chances of survival for
the patients.
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